ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly baqsimi (nasal glucagon) — U.S. revenue ($M) [legacy] ($M)
Annual figures from Eli Lilly's filings and investor materials
Latest, FY2024
2.50
Period ended Dec 31, 2024
Change on a year earlier
-99.6%
646 in FY2023
History
4 years
Since FY2021
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Baqsimi (nasal glucagon) — U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 2.50 | -99.6% | Form 10-K (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 646 | +484.9% | Form 10-K (filed 2025-02-19) ↗ |
| FY2022 | Dec 31, 2022 | 110 | +14.5% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 96.4 | – | Form 10-K (filed 2024-02-21) ↗ |
Cite this data
StockData. (2026). Eli Lilly Baqsimi (nasal glucagon) — U.S. revenue ($M) [legacy] ($M), annual FY2021–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_baqsimi_us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.